Gene therapy for peripheral arterial disease

Bibliography

• European Working Group on Critical Limb Ischaemia, American Heart Association. Second European Consensus Document on chronic critical leg ischemia. Circulation 1991;84:IV1-26
   PubMedGoogle Scholar
• Check E. Gene therapy: shining hopes dented - but not dashed. Nature 2002;420:735
   PubMed Web of Science ®Google Scholar
• Dormandy J, Mahir M, Ascady G, et al. Fate of the patient with chronic leg ischaemia. A review article. J Cardiovasc Surg (Torino) 1998;30:50-7
   Google Scholar
• Rutherford RB, Flanigan DP, Gupta SK, et al. Suggested standards for reports dealing with lower extremity ischemia. Prepared by the ad hoc committee on reporting standards, society for vascular surgery/north american chapter, international society for cardiovascular surgery. J Vasc Surg 1986;4:80-94
   PubMed Web of Science ®Google Scholar
• Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999;286:2244-5
   PubMed Web of Science ®Google Scholar
• Lee RJ, Springer ML, Blanco-Bose WE, et al. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000;102:898-901
   PubMed Web of Science ®Google Scholar
• Springer ML, Chen AS, Kraft PE, et al. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell 1998;2:549-58
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Shah M, Luciano A, et al. Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve. Circulation 2001;104:753-5
   PubMed Web of Science ®Google Scholar
• Mäkinen K, Manninen H, Hedman M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002;6:127-33
   PubMed Web of Science ®Google Scholar
• Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-64
   PubMed Web of Science ®Google Scholar
• Isner JM, Pieczek A, Schainfeld R, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996;348:370-4
   PubMed Web of Science ®Google Scholar
• Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114-23
   PubMed Web of Science ®Google Scholar
• Isner JM, Baumgartner I, Rauh G, et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 1998;28:964-5
   PubMed Web of Science ®Google Scholar
• Kusumanto YH, van Weel V, Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 2006;17:683-91
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Mohler ER, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003;108:1933-8
   PubMed Web of Science ®Google Scholar
• Muona K, Makinen K, Hedman M, et al. 10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb. Gene Ther 2012;19:392-5
   PubMed Web of Science ®Google Scholar
• Comerota AJ, Throm RC, Miller KA, et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 2002;35:930-6
   PubMed Web of Science ®Google Scholar
• Nikol S, Baumgartner I, Van Belle E, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008;16:972-8
   PubMed Web of Science ®Google Scholar
• Belch J, Hiatt WR, Baumgartner I, et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011;377:1929-37
   PubMed Web of Science ®Google Scholar
• Baumgartner I, Chronos N, Comerota A, et al. Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia. Mol Ther 2009;17:914-21
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Yasuda K, Iwai T, et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 2010;17:1152-61
   PubMed Web of Science ®Google Scholar
• Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci 2010;86:588-610
   PubMed Web of Science ®Google Scholar
• Kaga T, Kawano H, Sakaguchi M, et al. Hepatocyte growth factor stimulated angiogenesis without inflammation: differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor. Vascul Pharmacol 2012;57:3-9
   PubMed Web of Science ®Google Scholar
• Morishita R, Nakamura S, Hayashi S, et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 1999;33:1379-84
   PubMed Web of Science ®Google Scholar
• Hayashi S, Morishita R, Nakamura S, et al. Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells. Circulation 1999;100:II301-8
   PubMed Web of Science ®Google Scholar
• Taniyama Y, Morishita R, Hiraoka K, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation 2001;104:2344-50
   PubMed Web of Science ®Google Scholar
• Taniyama Y, Morishita R, Aoki M, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther 2001;8:181-9
   PubMed Web of Science ®Google Scholar
• Hiraoka K, Koike H, Yamamoto S, et al. Enhanced therapeutic angiogenesis by cotransfection of prostacyclin synthase gene or optimization of intramuscular injection of naked plasmid DNA. Circulation 2003;108:2689-96
   PubMed Web of Science ®Google Scholar
• Koike H, Morishita R, Iguchi S, et al. Enhanced angiogenesis and improvement of neuropathy by cotransfection of human hepatocyte growth factor and prostacyclin synthase gene. FASEB J 2003;17:779-81
   PubMed Web of Science ®Google Scholar
• Matsuki A, Yamamoto S, Nakagami H, et al. No influence of tumor growth by intramuscular injection of hepatocyte growth factor plasmid DNA: safety evaluation of therapeutic angiogenesis gene therapy in mice. Biochem Biophys Res Commun 2004;315:59-65
   PubMed Web of Science ®Google Scholar
• Morishita R, Makino H, Aoki M, et al. Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler Thromb Vasc Biol 2011;31:713-20
   PubMed Web of Science ®Google Scholar
• Makino H, Aoki M, Hashiya N, et al. Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease. Arterioscler Thromb Vasc Biol 2012;32:2503-9
   PubMed Web of Science ®Google Scholar
• Powell RJ, Simons M, Mendelsohn FO, et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008;118:58-65
   PubMed Web of Science ®Google Scholar
• Powell RJ, Goodney P, Mendelsohn FO, et al. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. J Vasc Surg 2010;52:1525-30
   PubMed Web of Science ®Google Scholar
• Henry TD, Hirsch AT, Goldman J, et al. Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study. Gene Ther 2011;18:788-94
   PubMed Web of Science ®Google Scholar
• Saeed M, Martin A, Ursell P, et al. MR assessment of myocardial perfusion, viability, and function after intramyocardial transfer of VM202, a new plasmid human hepatocyte growth factor in ischemic swine myocardium. Radiology 2008;249:107-18
   PubMed Web of Science ®Google Scholar
• Ajroud-Driss S, Christiansen M, Allen JA, et al. Phase 1/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy. Mol Ther 2013;21:1279-86
   PubMed Web of Science ®Google Scholar
• Grines CL, Watkins MW, Helmer G, et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-7
   PubMed Web of Science ®Google Scholar
• Grines CL, Watkins MW, Mahmarian JJ, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003;42:1339-47
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Olin J, Deitcher S, et al. Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation 2007;115:1234-43
   PubMed Web of Science ®Google Scholar
• Tachibana K, Tachibana S. Albumin microbubble echo-contrast material as an enhancer for ultrasound accelerated thrombolysis. Circulation 1995;92:1148-50
   PubMed Web of Science ®Google Scholar
• Bao S, Thrall BD, Miller DL. Transfection of a reporter plasmid into cultured cells by sonoporation in vitro. Ultrasound Med Biol 1997;23:953-9
   PubMed Web of Science ®Google Scholar
• Shohet R V, Chen S, Zhou YT, et al. Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. Circulation 2000;101:2554-6
   PubMed Web of Science ®Google Scholar
• Taniyama Y, Tachibana K, Hiraoka K, et al. Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther 2002;9:372-80
   PubMed Web of Science ®Google Scholar
• Taniyama Y, Tachibana K, Hiraoka K, et al. Local delivery of plasmid DNA into rat carotid artery using ultrasound. Circulation 2002;105:1233-9
   PubMed Web of Science ®Google Scholar
• Shimamura M, Sato N, Taniyama Y, et al. Gene transfer into adult rat spinal cord using naked plasmid DNA and ultrasound microbubbles. J Gene Med 2005;7:1468-74
   PubMed Web of Science ®Google Scholar
• Endoh M, Koibuchi N, Sato M, et al. Fetal gene transfer by intrauterine injection with microbubble-enhanced ultrasound. Mol Ther 2002;5:501-8
   PubMed Web of Science ®Google Scholar
• Suzuki G. Recent progress in plant reproduction research: the story of the male gametophyte through to successful fertilization. Plant Cell Physiol 2009;50:1857-64
   PubMed Web of Science ®Google Scholar
• Unger EC, Hersh E, Vannan M, et al. Local drug and gene delivery through microbubbles. Prog Cardiovasc Dis 2001;44:45-54
   PubMed Web of Science ®Google Scholar
• Kudo N, Okada K, Yamamoto K. Sonoporation by single-shot pulsed ultrasound with microbubbles adjacent to cells. Biophys J 2009;96:4866-76
   PubMed Web of Science ®Google Scholar
• Li T, Tachibana K, Kuroki M, et al. Gene transfer with echo-enhanced contrast agents: comparison between Albunex, Optison, and Levovist in mice – initial results. Radiology 2003;229:423-8
   PubMed Web of Science ®Google Scholar
• Juffermans LJM, Dijkmans PA, Musters RJP, et al. Transient permeabilization of cell membranes by ultrasound-exposed microbubbles is related to formation of hydrogen peroxide. Am J Physiol Heart Circ Physiol 2006;291:H1595-601
   PubMed Web of Science ®Google Scholar
• Mukherjee D, Wong J, Griffin B, et al. Ten-fold augmentation of endothelial uptake of vascular endothelial growth factor with ultrasound after systemic administration. J Am Coll Cardiol 2000;35:1678-86
   PubMed Web of Science ®Google Scholar
• Cui Z, Baizer L, Mumper RJ. Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device. J Biotechnol 2003;102:105-15
   PubMed Web of Science ®Google Scholar
• Mitragotri S. Current status and future prospects of needle-free liquid jet injectors. Nat Rev Drug Discov 2006;5:543-8
   PubMed Web of Science ®Google Scholar
• Kunugiza Y, Tomita N, Taniyama Y, et al. Acceleration of wound healing by combined gene transfer of hepatocyte growth factor and prostacyclin synthase with Shima Jet. Gene Ther 2006;13:1143-52
   PubMed Web of Science ®Google Scholar
• Sawamura D, Ina S, Itai K, et al. In vivo gene introduction into keratinocytes using jet injection. Gene Ther 1999;6:1785-7
   PubMed Web of Science ®Google Scholar
• Nakagawa A, Makino H, Aoki M, et al. Improvement of survival of skin flaps by combined gene transfer of hepatocyte growth factor and prostacyclin synthase. J Gene Med 2007;9:1087-94
   PubMed Web of Science ®Google Scholar
• Walther W, Siegel R, Kobelt D, et al. Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer. Clin Cancer Res 2008;14:7545-53
   PubMed Web of Science ®Google Scholar
• Walther W, Stein U, Fichtner I, et al. Intratumoral low-volume jet-injection for efficient nonviral gene transfer. Mol Biotechnol 2002;21:105-15
   PubMed Web of Science ®Google Scholar
• Walther W, Stein U, Fichtner I, et al. Nonviral in vivo gene delivery into tumors using a novel low volume jet-injection technology. Gene Ther 2001;8:173-80
   PubMed Web of Science ®Google Scholar
• Choi AH-C, Smiley K, Basu M, et al. Protection of mice against rotavirus challenge following intradermal DNA immunization by Biojector needle-free injection. Vaccine 2007;25:3215-18
   PubMed Web of Science ®Google Scholar
• Hallermalm K, Johansson S, Bråve A, et al. Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer. Scand J Immunol 2007;66:43-51
   PubMedGoogle Scholar
• Soboll G, Hussey SB, Whalley JM, et al. Antibody and cellular immune responses following DNA vaccination and EHV-1 infection of ponies. Vet Immunol Immunopathol 2006;111:81-95
   PubMed Web of Science ®Google Scholar
• Dégano P, Sarphie DF, Bangham CR. Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect system. Vaccine 1998;16:394-8
   PubMed Web of Science ®Google Scholar
• Tacket CO, Roy MJ, Widera G, et al. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 1999;17:2826-9
   PubMed Web of Science ®Google Scholar
• Breathnach CC, Rudersdorf R, Lunn DP. Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination. Vet Immunol Immunopathol 2004;98:127-36
   PubMed Web of Science ®Google Scholar
• Wolff JA, Williams P, Acsadi G, et al. Conditions affecting direct gene transfer into rodent muscle in vivo. Biotechniques 1991;11:474-85
   PubMed Web of Science ®Google Scholar
• Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease Meta-analysis and systematic review of the literature. Atherosclerosis 2010;209:10-17
   PubMed Web of Science ®Google Scholar
• Benoit E, O'Donnell TF, Patel AN. Safety and efficacy of autologous cell therapy in critical limb ischemia: a systematic review. Cell Transplant 2013;22:545-62
   PubMed Web of Science ®Google Scholar
• Teraa M, Sprengers RW, van der Graaf Y, et al. Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials. Ann Surg 2013;258:922-9
   PubMed Web of Science ®Google Scholar
• Losordo DW, Kibbe MR, Mendelsohn F, et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv 2012;5:821-30
   PubMed Web of Science ®Google Scholar
• Jarajapu YPR, Caballero S, Verma A, et al. Blockade of NADPH oxidase restores vasoreparative function in diabetic CD34+ cells. Invest Ophthalmol Vis Sci 2011;52:5093-104
   PubMed Web of Science ®Google Scholar
• Chen F, Tan Z, Dong CY, et al. Combination of VEGF(165)/Angiopoietin-1 gene and endothelial progenitor cells for therapeutic neovascularization. Eur J Pharmacol 2007;568:222-30
   PubMed Web of Science ®Google Scholar
• Ymamoto Y, Matsuura T, Narasaki G, et al. Synergistic effects of autologous cell and hepatocyte growth factor gene therapy for neovascularization in a murine model of hindlimb ischemia. Am J Physiol Heart Circ Physiol 2009;297:H1329-36
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Kondo T, Inoue N, et al. Combination of in vivo angiopoietin-1 gene transfer and autologous bone marrow cell implantation for functional therapeutic angiogenesis. Arterioscler Thromb Vasc Biol 2006;26:1465-72
   PubMed Web of Science ®Google Scholar
• Fierro FA, Kalomoiris S, Sondergaard CS, et al. Effects on proliferation and differentiation of multipotent bone marrow stromal cells engineered to express growth factors for combined cell and gene therapy. Stem Cells 2011;29:1727-37
   PubMed Web of Science ®Google Scholar